(Reuters) – Sun Pharmaceutical Industries Ltd on Friday asked India’s capital markets regulator to look into a media report about an alleged complaint by a whistleblower that led to a sell-off in the company’s shares.

In a letter to the Securities and Exchange Board of India (SEBI), Sun Pharma said there was “great asymmetry in the information circulating between analysts, investors and media leading to intense speculation.”